Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cytomegalovirus (CMV) Treatment Market

Cytomegalovirus (CMV) Treatment Market Analysis

  • Report ID: GMI8288
  • Published Date: Feb 2024
  • Report Format: PDF

CMV Treatment Market Analysis

Based on the drug type, the global market is classified into valganciclovir, ganciclovir, cidofovir, foscarnet, and other drug types. The ganciclovir drug type dominated the market with revenue of USD 162.5 million in 2023.

  • Ganciclovir is a first-line antiviral medication for the treatment of CMV infections. It inhibits viral replication by targeting the viral DNA polymerase enzyme, making it an essential component of CMV treatment regimens. Its proven efficacy in managing CMV infections contributes to its widespread use in clinical practice.
  • Additionally, the increasing number of solid organ and hematopoietic stem cell transplants globally contributes to a surging incidence of CMV infections among transplant recipients, thereby bolstering segment expansion.


Cytomegalovirus (CMV) Treatment Market, By Application (2023)

Based on application, the cytomegalovirus treatment market is classified into stem cell transplantation, organ transplantation, congenital CMV infection, and other applications. The stem cell transplantation segment held the highest business share of 38.3% in 2023.

  • Stem cell transplantation stands to gain from the integration of new cell types, presenting significant opportunities for companies to fortify their market presence. Consequently, the number of companies venturing into cell therapy development has markedly increased in recent years.
  • Moreover, rising government and private sector funding for stem cell therapy clinical trials, the implementation of effective stem cell therapy manufacturing guidelines, and the proven effectiveness of products are expected to be key growth drivers for the market segment.

Based on route of administration, the cytomegalovirus treatment market is classified into oral and intravenous. The intravenous segment is expected to hold the highest revenue throughout the forecast period.

  • The IV route of administration is preferred in acute care settings such as hospitals and infusion centers, where patients with severe CMV infections, such as CMV retinitis or systemic CMV disease, require immediate and intensive treatment. Thus, demand for injectable in CMV treatment is anticipated to grow in forthcoming years.
  • Additionally, with the increasing emphasis on outpatient care and the shift towards ambulatory infusion services, there is a growing demand for IV CMV treatment options that can be administered in outpatient settings. This trend is driven by factors such as patient convenience, cost-effectiveness, and the desire to minimize hospital admissions.

Based on distribution channel, the CMV treatment market is classified into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies dominated the market with revenue of USD 219.9 million in 2023.

  • Hospital pharmacies serve as a vital healthcare facility where patients receive specialized care, particularly those undergoing organ transplantation or with weaker immune systems. Hospital pharmacists have a range of CMV medications and antiviral treatments, ensuring that patients receive early and effective care.
  • Hospital pharmacists serve as a key hub for CMV therapy since they are also prepared to manage the difficulties of treating CMV infections in a variety of patient demographics. Effective communication and coordination are further facilitated in the management of CMV patients by the collaborative character of healthcare teams in hospitals.


North America CMV Treatment Market, 2020 – 2032 (USD Million)

In 2023, North America secured a substantial market share in the global cytomegalovirus treatment market and is expected to dominate throughout the forecast period.

  • Factors such as the increasing consumer awareness, growing incidences of cytomegalovirus infections, and the presence of key market players are some of the prominent factors that will contribute significantly to the market's expansion.
  • For instance, according to an article released by NINDS in July 2022, CMV infects around 50% to 80% of adults each year by the age of 40 and is one of the most common congenital diseases in the U.S.


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cytomegalovirus (CMV) treatment industry size reached USD 474.6 million in 2023 and is poised to expand at 6.6% CAGR from 2024-2032 propelled by increasing awareness and prevalence of CMV infection, as well as the development of new and effective treatments.

The ganciclovir drug type generated USD 162.5 million in revenue in 2023 and is estimated to record high demand by 2032 driven by the increasing number of solid organ and hematopoietic stem cell transplants globally.

North America CMV treatment market is set to exhibit robust growth between 2024 and 2032 owing to the increasing consumer awareness, growing incidences of cytomegalovirus infections, and the presence of key market players in the region.

Some of the major companies engaged in the CMV treatment industry are Chimerix, Clinigen Group PLC, F. Hoffmann-La Roche Ltd, Genentech Inc., Gilead Sciences, Inc., Merck & Co. Inc, Mylan N.V, Pfizer, Inc., Takeda Pharmaceuticals, Teva Pharmaceuticals Inc, and Thermo Fisher Scientific Inc.

Cytomegalovirus Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 261
  • Countries covered: 19
  • Pages: 165
 Download Free Sample